Nitrosamine Analysis: Detection and Quantification of Genotoxic Impurities
Nitrosamine analysis is the trace-level detection and quantification of N-nitrosamines classified as probable human carcinogens in APIs, excipients and finished drug products. The study combines LC-MS/MS and GC-MS to measure each nitrosamine against its acceptable daily intake limit, supporting ICH M7 risk assessment, batch release and regulatory submission.
What is nitrosamine analysis?
Nitrosamines are N-nitroso compounds formed when a secondary or tertiary amine reacts with a nitrosating agent, residual nitrite, or by-products generated under acidic conditions. Several are classified as probable human carcinogens, which is why FDA, EMA and other regulators require risk assessment and, where warranted, parts-per-billion-level quantification in drug products.
The risk is not confined to API synthesis. Nitrosamines can also form through interaction between the active, excipients and packaging materials, or through degradation during storage, the best-known case being NDMA formation in ranitidine over shelf life, unrelated to the original manufacturing process.
The analysis combines two layers: a documentary risk assessment, which identifies whether the synthesis route, excipients or manufacturing process create formation potential, and an analytical layer, trace-level mass spectrometry quantification, when the identified risk calls for experimental confirmation.
Nitrosamines monitored and reference limits
Seven to eight compounds account for most of the regulatory cases documented to date. Each has its own acceptable daily intake (AI) limit, set from a carcinogenicity risk assessment.
| Compound | Name | Reference AI |
|---|---|---|
| NDMA | N-Nitrosodimethylamine | 96 ng/day |
| NDEA | N-Nitrosodiethylamine | 26.5 ng/day |
| NMBA | N-Nitroso-N-methyl-4-aminobutyric acid | 96 ng/day |
| NDIPA | N-Nitrosodiisopropylamine | 26.5 ng/day |
| NEIPA | N-Nitrosoethylisopropylamine | 26.5 ng/day |
| NMPA | N-Nitrosomethylphenylamine | 26.5 ng/day |
| NDBA | N-Nitrosodibutylamine | 26.5 ng/day |
Reference values most frequently cited in FDA guidance. Limits are revised periodically and can vary by regulatory authority and by product; the risk assessment in the study always applies the value current in the applicable guidance.
From technique to decision
Method choice depends on the volatility and polarity of the target nitrosamine and on the product matrix. No technique enters the scope without answering a question the risk assessment raised.
| Technique | What it measures | What decision it supports |
|---|---|---|
| LC-MS/MS | Polar, non-volatile nitrosamines at trace level, directly in the API, excipient or finished product, the typical case for sartans and metformin. | Whether a specific batch is within the acceptable daily intake limit for the nitrosamine in question. |
| GC-MS (headspace) | Volatile nitrosamines by headspace sampling, without extensive matrix extraction. | Whether a volatile nitrosamine is present without the interference risk a liquid extraction would introduce. |
| Chromatography · Supporting HPLC/UPLC | Separation of the target nitrosamine from excipients and degradation products ahead of mass detection. | Whether the product matrix requires an additional separation step to avoid a false negative or signal suppression. |
| Analytical method validation | Specificity, linearity, accuracy, precision, limit of detection and limit of quantification of the method, against the real product matrix. | Whether the method is sensitive enough to reliably quantify below the acceptable daily intake limit, not just below a generic laboratory limit. |
The analytical workflow
Every product runs through the same logical sequence, with analytical scope adjusted to the risk identified at the first stage; not every product assessed needs experimental quantification.
Documentary risk assessment (ICH M7)
Critical review of the API's synthesis route, of precursors carrying a secondary or tertiary amine, of potential nitrosating agents, of excipients, of the manufacturing process, and of storage conditions. Classifies the product's nitrosamine formation potential before any bench assay.
Risk assessment report
Method development and validation
An LC-MS/MS or GC-MS method specific to the nitrosamine and the product matrix, with selectivity against the rest of the formulation. Validation of specificity, linearity, accuracy, precision and sensitivity (LOD/LOQ) to the applicable regulatory requirements.
A validated method, with sensitivity traced to the acceptable intake limit
Confirmatory quantification
Trace-level quantification of each nitrosamine flagged as a risk, per batch or per stability study point, with the result expressed as concentration and converted to daily intake from the maximum product dose.
Quantitative result per nitrosamine, in ng/g and ng/day
Interpretation and regulatory support
Comparison of each result against the current acceptable daily intake limit, root-cause discussion where applicable, and evidence organised in the format required for submission to ANVISA, FDA or EMA.
An interpreted report, with a compliance opinion
Applications
The same analytical capability supports distinct fronts of risk and regulatory decision.
Synthesis risk
APIs with secondary or tertiary amines
Sartans, metformin and other classes whose synthesis route or regulatory history has already linked the API to nitrosamine formation.
Generics & similars
Registration dossier and batch release
Quantitative, batch-level evidence to support ANVISA or other regulatory registration and routine release, with results traced to the product's acceptable intake limit.
CDMO & contract manufacturers
New-process risk assessment
Documentary assessment before commercial production begins, identifying precursors and process steps with formation potential.
Stability
Formation during storage
Investigation of nitrosamine formation over shelf life, when the cause sits in finished-product degradation rather than in API synthesis.
What you receive
An interpreted technical report, not a set of loose chromatograms.
Data and evidence
- Chromatograms and mass spectra per nitrosamine tested
- Method validation data: specificity, linearity, accuracy, precision, LOD and LOQ
- Quantitative result per compound, in concentration and in estimated daily intake
- Direct comparison against the applicable acceptable daily intake limit
Interpretation and conclusions
- Compliance opinion against current guidance (ICH M7, FDA, EMA, ANVISA)
- Root-cause discussion when the result indicates a synthesis, process or degradation risk
- Mitigation or process-adjustment recommendations, where applicable
- Evidence organised in a format that supports regulatory submission
Scope and turnaround
Scope is risk-oriented: the documentary assessment defines which nitrosamines require experimental quantification, avoiding assays that would not change the regulatory decision.
- Documentary risk assessment before any bench assay
- Analytical scope limited to nitrosamines with identified formation potential
- A validated method with sensitivity traced to the compound's acceptable intake limit
- Results expressed both as concentration and as estimated daily intake
- Suited to one-off assessment, routine batch release and stability studies
Frequently asked questions
What are nitrosamine impurities?
- They are N-nitroso compounds formed when a secondary or tertiary amine reacts with a nitrosating agent. Several nitrosamines are classified as probable human carcinogens, which is why regulatory agencies have set acceptable daily intake limits for drug products.
Why are nitrosamines a risk in drug products?
- Because they can form during API synthesis, through interaction between the active, excipients and packaging, or through degradation over storage, often at very low concentrations that can still exceed the acceptable daily intake limit set by the toxicological risk assessment.
Which drugs carry the highest risk of containing nitrosamines?
- Sartans (losartan, valsartan, irbesartan) and metformin account for most documented cases, because they contain or generate secondary or tertiary amines in the synthesis route. Historical cases also involved ranitidine, through formation during storage rather than during manufacturing.
What is the difference between LC-MS/MS and GC-MS for nitrosamine analysis?
- LC-MS/MS is used for polar, non-volatile nitrosamines, directly in the API or finished-product matrix. GC-MS with headspace sampling is used for volatile nitrosamines, avoiding the extensive extraction a complex matrix would otherwise require. The choice depends on the target nitrosamine and the matrix.
What is the acceptable daily intake limit for nitrosamines?
- It varies by compound: the most cited reference values include 96 ng/day for NDMA and NMBA, and 26.5 ng/day for NDEA, NDIPA, NEIPA, NMPA and NDBA. These limits are revised periodically by regulatory agencies and can differ by product; the assessment always applies the value current in the applicable guidance at the time of the study.
Does ANVISA require nitrosamine testing?
- ANVISA follows the international ICH M7 guidance and requires genotoxic impurity risk assessment, including nitrosamines, as part of the toxicological safety evidence for APIs and finished products registered in Brazil.
What is a nitrosamine risk assessment under ICH M7?
- It is the documentary review of the API's synthesis route, of precursors carrying a secondary or tertiary amine, of excipients, of the manufacturing process and of storage conditions, to classify nitrosamine formation potential before deciding whether experimental quantification is needed.
How does a nitrosamine form during manufacturing or storage?
- The most common route is the reaction of a secondary or tertiary amine, present in the API, in an excipient, or as a by-product, with residual nitrite under acidic conditions. Contaminated raw material, solvent or reagent, and degradation of the product itself over shelf life, are also documented routes.
Does the analytical method need to be validated for every product?
- Yes. Validation confirms the method is selective against that product's specific matrix and sensitive enough to reliably quantify below that nitrosamine's acceptable daily intake limit; a generic method does not substitute for that check.
How long does a nitrosamine analysis study take?
- It depends on the scope set after the risk assessment: routine quantification with an already-validated method is faster than a study requiring method development and validation specific to the product matrix. Turnaround is set in the proposal, after the initial risk assessment.
Is the information submitted handled confidentially?
- Yes. Scope, samples, results and the existence of the study are treated as client confidential information, under a confidentiality agreement signed before samples are sent.
What product types can be analysed?
- APIs, excipients, finished products and stability-study samples. Analytical scope and extraction matrix are adjusted to the sample type and to the target nitrosamine identified in the risk assessment.
Services that complement nitrosamine analysis
Request a proposal
Scope is risk-oriented: the documentary assessment defines which nitrosamines require experimental quantification, avoiding assays that would not change the regulatory decision.
Request a proposal